Cardiovascular Diseases
Disease State Hub
Featured
07/27/2026
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
07/27/2026
07/24/2026
Anthony Calabro, MA
A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...
07/24/2026
07/16/2026
Anthony Calabro, MA
The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.
07/16/2026
Interactive Features
04/18/2026
Anthony Calabro, MA
A 29-year-old woman with systemic lupus erythematosus and a history of hypertension presented to the emergency department with acute chest pain and lower extremity paresthesia.
04/18/2026
03/26/2026
Kate Young
Diabetes mellitus represents one of the most powerful and prevalent cardiometabolic risk factors facing U.S. adults today. Test your knowledge about diabetes prevalence.
03/26/2026
03/23/2026
Ashton L. Stahl
Test your knowledge on the prevalence of FDA-approved indications for novel cardiovascular-kidney-metabolic therapies and the implications for clinical practice.
03/23/2026
03/10/2026
Kate Young
The 2026 Cardiovascular Statistics report provides a comprehensive review of trends in major cardiovascular risk factors—including hypertension, diabetes, obesity, dyslipidemia, and smoking—as well as the 5...
03/10/2026
01/13/2026
Anthony Calabro, MA
Consultant360’s Top 5 Video Interviews of 2025 features compelling discussions on acne management and isotretinoin retrial strategies, esophageal squamous cell carcinoma pathophysiology and knowledge gaps,...
01/13/2026
Clinical Insights
03/06/2026
Anum Saeed, MD
In this Q&A, Anum Saeed, MD discusses how cardiologists must think beyond LDL and blood pressure, leveraging GLP-1 receptor agonists, SGLT-2 inhibitors, and emerging therapies to reduce cardiovascular...
03/06/2026
NUTRITION411: THE PODCAST, EP. 54
NUTRITION411: THE PODCAST, EP. 54
02/11/2026
Lisa Jones, MA, RDN, LDN, FAND; Grace A. Derocha, MBA, RD, CDCES
In part two of this four-part series, Lisa Jones, MA, RDN, LDN, FAND, and Grace A. Derocha, MBA, RD, CDCES, registered dietitian and a certified diabetes care and education specialist, discuss how...
02/11/2026
02/05/2026
Brian A. Bergmark, MD
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
02/05/2026
Nutrition411: The Podcast, Ep. 53
Nutrition411: The Podcast, Ep. 53
02/04/2026
Lisa Jones, MA, RDN, LDN, FAND; Grace A. Derocha, MBA, RD, CDCES
In part one of this four-part series, Lisa Jones, MA, RDN, LDN, FAND, and Grace A. Derocha, MBA, RD, CDCES, registered dietitian and a certified diabetes care and education specialist, discuss the latest...
02/04/2026
04/15/2025
Rachel Lampert, MD
In this video, Rachel Lampert, MD, Robert W. Berliner Professor of Internal Medicine at the Yale School of Medicine, reviews her presentation at the American College of Cardiology 2025 Annual Meeting,...
04/15/2025
